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Summary  Atrial  ﬁbrillation  (AF)  is  the  most  common  rhythm  disturbance.  Among  the
major thromboembolic  complications  associated  with  AF,  strokes  are  foremost,  with  a  4.4%
yearly incidence  in  the  absence  of  preventive  treatment.  Therefore,  the  prevention  of  these
embolic accidents  is  a  priority.  While  proof  of  the  efﬁcacy  of  oral  anticoagulants  (OACs)
for this  indication  is  long-standing  and  convincing,  they  are  associated  with  haemorrhagic
complications.  Consequently,  their  prescription  is  based  on  an  estimate  of  the  risk  (haemo-
rrhagic complications)/beneﬁt  (thromboembolic  prevention)  ratio.  In  a  patient  subset  at  high
thromboembolic  and  haemorrhagic  risk,  whether  to  prescribe  or  abstain  from  prescribing  an  OAC
is a  challenging  decision,  and  an  alternative  means  of  thromboembolic  prevention  is  desirable.
Percutaneous  occlusion  of  the  left  atrial  appendage  (LAA)  is  an  alternative,  interventional,  non-
pharmacological  treatment  that  has  been  used  widely  in  Europe  and  for  a  few  years  in  France,
with encouraging  results.  However,  it  remains  an  invasive  procedure  with  a  low  level  of  proof  in
comparison  with  OACs.  Moreover,  the  indications,  the  procedural  environment  and  pre-per-post
procedural  patient  management  are  major  questions  about  this  technique,  with  consequences
on its  efﬁcacy  and  risk/beneﬁt  ratio.  This  document,  composed  by  consensus  among  experts  in
the ﬁeld,  is  an  in-depth  review  of  this  new  therapy.
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Résumé  La  ﬁbrillation  auriculaire  (FA)  est  le  trouble  du  rythme  le  plus  fréquent  avec  une
prévalence  de  près  de  2  %  de  la  population.  Elle  peut  être  associée  à  des  complications
thromboemboliques  sévères  avec  principalement  un  risque  d’accident  vasculaire  cérébral  (AVC)
ischémique  dont  l’incidence  annuelle  est  de  4,4  %  sans  traitement  préventif.  On  estime  que
25 %  des  130  000  AVC  ischémiques  annuels  en  France  sont  secondaires  à  une  FA  et  que  70  %
d’entre eux  entraîneront  le  décès  du  patient  ou  des  séquelles  majeures.  La  prévention  de  ces
accidents  emboliques  est  donc  une  priorité.  Les  anticoagulants  oraux  (ACO)  ont  largement  et
depuis longtemps  montré  leur  efﬁcacité  dans  cette  indication.  Cependant,  ils  sont  associés  à
des complications  hémorragiques.  Leur  prescription  repose  sur  une  estimation  du  ratio  bénéﬁce
(prévention  thromboembolique)/risque  (complications  hémorragiques).  Dans  certaines  popula-
tions, le  risque  thromboembolique  et  le  risque  hémorragique  élevés  imposent  un  choix  difﬁcile
entre la  prescription  ou  l’abstention  d’un  ACO.  Des  alternatives  aux  ACO  pour  la  prévention
thromboembolique  sont  donc  souhaitables.  L’occlusion  percutanée  de  l’auricule  gauche  (AG)
est une  alternative  proposée  depuis  plusieurs  années,  avec  des  résultats  encourageants.  Il  s’agit
d’un traitement  interventionnel  non  pharmacologique,  largement  utilisé  en  Europe  et  depuis
quelques années  en  France.  Il  nous  a  paru  important  de  préciser  les  modalités  de  cette  nouvelle
thérapeutique  dans  ce  documen
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of  the  left  atrium,  are  widely  variable.  While  the  car-Background
With  a  nearly  2%  prevalence  in  the  general  population,  atrial
ﬁbrillation  (AF)  is  the  most  common  rhythm  disturbance.
Among  the  major  thromboembolic  complications  associ-
ated  with  AF,  ischaemic  cerebral  vascular  accidents  (CVAs)
are  foremost,  with  a  4.4%  yearly  incidence  in  the  absence
of  preventive  treatment.  Furthermore,  among  the  130,000
ischaemic  CVAs  occurring  in  France  every  year,  the  esti-
mated  proportion  secondary  to  AF  is  25%,  of  which  70%
are  fatal  or  leave  major  sequelae.  Therefore,  the  preven-
tion  of  these  embolic  accidents  is  a  priority.  While  proof
of  the  efﬁcacy  of  oral  anticoagulants  (OACs)  for  this  indi-
cation  is  long-standing  and  convincing,  they  are  associated
with  haemorrhagic  complications.  Consequently,  their  pre-
scription  is  based  on  an  estimate  of  the  risk  (haemorrhagic
complications)/beneﬁt  (thromboembolic  prevention)  ratio.
In  a  patient  subset  at  high  thromboembolic  and  haemorrha-
gic  risk,  whether  to  prescribe  or  abstain  from  prescribing  an
d
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tt  émanant  d’un  consensus  d’experts.
AC  is  a  challenging  decision,  and  an  alternative  means  of
hromboembolic  prevention  is  desirable.
Percutaneous  occlusion  of  the  left  atrial  appendage  (LAA)
s  an  alternative,  interventional,  non-pharmacological  treat-
ent  that  has  been  used  widely  in  Europe  and  for  a  few
ears  in  France,  with  encouraging  results.  This  document,
omposed  by  consensus  among  experts  in  the  ﬁeld,  is  an
n-depth  review  of  this  new  therapy.
tate of the art
ationale
he  size  and  morphology  of  the  LAA,  with  a  single  or  multi-
le  lobes  and  an  ostium  located  on  the  anterolateral  aspectiovascular  sources  of  thromboembolisms  are  multiple,  in
on-valvular  AF,  the  migration  through  the  systemic  circula-
ion  of  a  thrombus  formed  in  the  LAA  is  the  main  cause.
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ased  on  anatomopathological,  surgical  and  echocardiog-
aphic  data,  the  LAA  is  the  site  of  thrombus  formation  in
pproximately  90%  of  cases  [1],  a  percentage  that  decreases
ith  the  non-valvular  characteristics  of  AF,  the  instability  of
he  international  normalized  ratio  and  the  worsening  of  left
entricular  systolic  function  [2].  Thus,  it  seemed  ﬁtting  to
xamine  the  merit  of  excluding  or  occluding  the  LAA  as  a
eans  of  preventing  thromboembolisms  in  AF.
tudies of LAA exclusion or occlusion
urgical techniques
he  LAA  has  been  excluded  during  the  surgical  treatment
f  AF:  as  a  part  of  the  MAZE  procedure;  as  a  complement
o  valvular  or  non-valvular  cardiac  surgery;  and  during  a
edicated  procedure  via  thoracotomy.  However,  the  sam-
le  sizes  of  these  studies  were  generally  small,  precluding
he  drawing  of  ﬁrm  conclusions  with  respect  to  the  preven-
ive  efﬁcacy  of  the  procedure.  The  results  of  exclusion  plus
uture  of  the  LAA  have  been  more  predictable  than  those  of
uture  alone,  which  tends  to  be  leaky  [3].  The  randomized
ingle-centre  Left  Atrial  Appendage  Occlusion  Study  (LAAOS)
II,  comparing  surgical  exclusion  versus  preservation  of  the
AA  with  continuation  of  optimal  conventional  treatment,
t  the  time  of  cardiac  operations  performed  in  patients  in
F,  is  in  progress  and  is  expected  to  offer  an  answer  to  this
uestion  in  2016.
ercutaneous studies
hus  far,  four  implantable  devices  have  been  studied:  the
LAATO  system,  which  is  no  longer  pursued  commercially;
he  WatchmanTM system  (Boston  Scientiﬁc,  Maple  Grove,
N,  USA);  the  AmplatzerTM Cardiac  Plug  (ACP)  system  (St.
ude  Medical,  Minneapolis,  MN,  USA);  and  the  WaveCrestTM
ystem  (Coherex  Medical,  Salt  Lake  City,  UT,  USA),  which
as  few  published  data.  These  devices  are  all  implanted  via
ransseptal  catheterization.  The  LARIATTM system  (Sentre-
EART,  Inc.,  Redwood  City,  CA,  USA)  uses  another  technique
or  a  similar  purpose,  by  percutaneously  ligating  the  LAA
ia  an  endocardial/epicardial  approach.  Cardiac  imaging  is
ndispensable  for  the  performance  of  all  these  procedures,
oth  to  evaluate  the  anatomy  of  the  LAA,  which  varies
idely  among  individuals,  and  to  look  for  the  presence  of
 thrombus,  in  which  case  the  procedure  is  contraindicated.
chocardiographic  imaging,  which  must  be  performed  by
xpert  observers,  is  now  often  complemented  by  a  sectional
omographic  cardiac  scan.
ata from the PLAATO system
n  an  initial  non-randomized  study  of  the  PLAATO  system
n  111  patients,  implantation  of  the  device  was  tech-
ically  feasible  and  lowered  the  estimated  risk  of  CVAs
y  40—65%,  depending  on  the  thromboembolic  risk  [4].
his  was  conﬁrmed  in  61  patients  followed  for  5  years,
n  whom  the  rate  of  CVAs  was  3.8%  per  year,  compared
ith  a  predicted  risk  of  6.6%  per  year  by  the  CHADS2
core  [5].ata  from  the  ACP  system
he  ACP  has  been  studied  by  single  health  centres,  and  has
een  the  subject  of  several  multicentre  registries,  although
w
I
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ot  of  randomized  studies  [6—10].  A  comparative  study  with
arfarin  initiated  in  the  USA  has  been  halted.  In  Euro-
ean  studies,  device  implantation  was  successful  in  132
f  137  procedures  (96%)  and  major  complications  were
eported  in  10  of  137  procedures  (7%).  The  most  common
omplications  were  pericardial  effusions  with  or  without
amponade,  CVAs  and  migration  of  the  device.  Thromboses
n  the  surface  of  the  device  have  been  reported  in  three
atients  [11].
ata  from  the  Watchman  system
he  Watchman  system  is  the  only  system  that  has  been  stud-
ed  randomly  [12]. The  PROTECT-AF  trial  randomly  assigned
07  patients  with  non-valvular  AF  to  warfarin  versus  a
atchman  device,  in  a  2:1  ratio.  The  patients,  enrolled  by
9  medical  centres,  had  no  contraindications  to  treatment
ith  antivitamin  K.  This  was  a  non-inferiority  study,  with
fﬁcacy  endpoints  including  CVAs,  cardiovascular  death  and
ystemic  thromboembolisms,  and  safety  endpoints  including
ericardial  effusion,  device  embolization  and  major  hae-
orrhage.
The  recipients  of  Watchman  devices  received  warfarin  for
5  days  after  the  procedure  or  for  longer  in  case  of  resid-
al  leak  around  the  device,  at  which  time  they  underwent
aseline  transoesophageal  echocardiography  (TOE).  From  45
ays  onward,  dual  antiplatelet  therapy  (aspirin  75  mg  and
lopidogrel  75  mg,  daily)  was  administered  for  6  months
o  allow  endothelialization  of  the  device.  Continuation  of
spirin  (75  mg,  daily)  was  recommended  thereafter.  In  real-
ty,  antivitamin  K  therapy  was  discontinued  in  87%  of  the
atients  assigned  to  the  Watchman  device  at  45  days,  and
n  94%  at  2  years  of  follow-up.  Using  the  Rosendaal  method,
he  recipients  of  Watchman  devices  spent  66%  of  their  time
ith  an  international  normalized  ratio  between  2  and  3,
easured  every  2  weeks.
After  a  1065  patient-year  follow-up,  or  a mean  follow-
p  of  18  months,  the  non-inferiority  endpoint  was  reached,
onﬁrming  that  closing  the  LAA  in  this  population  with  AF  is
n  alternative  means  of  preventing  thromboembolic  events.
ith  an  incidence  of  4.8%,  pericardial  effusion  was  the  most
requent  complication.  The  rate  of  complications  decreased
rom  7.7%  in  PROTECT-AF  to  3.7%  in  the  CAP  registry  and  to
.2%  in  the  PREVAIL  study,  as  the  experience  of  operators
nd  medical  centres  increased  [13].
The  4-year  follow-up  of  PROTECT-AF  conﬁrmed  the  2-
ear  results,  with  the  ﬁrst  demonstration  of  a 34%  decrease
n  relative  all-cause  mortality  and  a  60%  decrease  in  cardio-
ascular  mortality  by  the  Watchman  system.  It  is,  however,
oteworthy  that:  this  study’s  sample  size  was  small  com-
ared  with  the  studies  completed  with  OACs;  mortality  was
ot  a  primary  criterion;  the  2.2  ±  1.2  median  CHADS2 score
as  low;  and  antivitamin  K  therapy  was  continued  for  sev-
ral  weeks  after  implantation  of  the  devices,  which  may
ave  contributed  to  the  results  observed  in  the  Watchman
roup.  The  Watchman  system  has  not  been  compared  with
irect  OACs.
ercutaneous occlusion of the LAA in patients
ith contraindications to  OACs
n  nearly  30%  of  patients,  treatment  with  an  OAC  was  dis-
ontinued  by  the  end  of  3  years  because  of  an  excessively
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high  estimated  risk  of  haemorrhagic  complications.  These
patients,  who  are  often  frail,  remain  exposed  to  a  high  risk
of  thromboembolic  events  [14].  In  the  ORBIT-AF  registry,  13%
of  10,130  patients  who  needed  OACs  for  AF  had  a  contraindi-
cation  at  the  time  of  inclusion:  a  history  of  haemorrhage  was
present  in  28%;  28%  of  patients  declined;  18%  presented  with
a  high  haemorrhagic  risk  ascertained  by  the  ATRIA  score;  18%
were  frail  or  fell  frequently;  10%  needed  dual  antiplatelet
therapy;  6%  could  not  be  controlled  or  comply  with  warfarin
treatment;  5%  had  concomitant  illnesses;  5%  had  histories  of
haemorrhagic  CVAs;  and  16%  had  miscellaneous  contraindi-
cations  [15].  These  patients  at  high  risk  of  ischaemic  CVAs
are  in  need  of  alternative  non-pharmacological  treatment,
such  as  percutaneous  occlusion  of  the  LAA.
ASAP,  a  prospective  registry  of  Watchman  system  recipi-
ents  presenting  with  absolute  contraindications  to  warfarin,
included  150  patients  with  a  median  CHADS2 score  of
2.8  ±  1.2  and  a  median  CHA2DS2-VASc  score  of  4.7  ±  1.7.
These  patients  received  aspirin  (75  mg,  daily)  and  clopido-
grel  (75  mg,  daily)  for  6  months  after  the  procedure.  The
implantation  success  rate  was  96%.  At  a  mean  follow-up  of
14.4  months,  13  of  150  patients  (8.7%)  experienced  a major
complication,  including:  ﬁve  pericardial  effusions,  two  of
which  were  evacuated  percutaneously  because  of  tampo-
nade;  two  device  embolizations,  one  of  which  migrated  to
the  descending  aorta  during  the  procedure,  and  both  of
which  were  percutaneously  extracted;  and  six  device  throm-
boses,  one  of  which  caused  a  CVA,  while  the  other  ﬁve
were  detected  during  a  follow-up  echocardiogram.  The  rates
of  ischaemic  and  haemorrhagic  CVAs  were  1.7%  and  0.6%,
respectively,  representing  a  64%  lower  relative  risk  than  in
a  similarly  ill  population,  after  correction  for  the  putative
protection  conferred  by  dual  antiplatelet  therapy  [16].  Sim-
ilar  results  were  observed,  with  a  55—65%  decrease  in  the
rate  of  CVAs  compared  with  the  expected  rate,  as  a  func-
tion  of  the  risk  score,  in  studies  of  the  ACP  in  the  presence
of  contraindications  to  OACs  [8,11,17].  These  encourag-
ing  results  need  to  be  conﬁrmed  in  a  randomized  study,
although  the  control  group  remains  to  be  deﬁned  (absence
of  antithrombotic  treatment,  antiplatelet  treatment),  with
a  target  population  estimated  at  between  10,000  and  30,000
patients,  according  to  the  report  issued  by  the  National  Com-
mittee  for  the  Evaluation  of  Medical  Devices  and  Health
Technologies  (CNEDiMTS)  [18].
Complications related to percutaneous
occlusion  of the LAA
The  most  frequent  complications  of  the  procedure  are
immediate  and,  to  some  degrees,  related  to  the  experience
of  the  operators.  The  inescapable  learning  curve,  estimated
at  30  procedures,  also  depends  on  previous  experience
with  transseptal  catheterization,  closure  of  atrial  septal
defects,  AF  ablation,  mitral  valvuloplasty,  etc.  The  various
studies  mentioned  earlier  (PROTECT-AF,  CAP  and  PREVAIL)
have  conﬁrmed  a  signiﬁcant  decrease  in  the  incidence  of
complications  with  increasing  experience.In  a  recent  literature  review,  the  incidences  (95%
conﬁdence  intervals)  of  complications  such  as  pericar-
dial  effusion  and  device  embolization  were  4.3%  (3.1—5.9)
and  3.9%  (2.7—5.6)  with  the  ACP  and  Watchman  systems,
r
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espectively,  while  the  incidence  of  CVAs  was  0.7%  (0.2—1.2)
19]. The  need  to  proceed  with  a  post-procedural  surgical
ntervention  was  2.2%  [20].  Thus,  while  rarely  needed,  one
ust  be  ready  to  proceed  with  surgery  expeditiously  in  these
atients,  who  are  usually  old  and  frail.
Once  the  learning  curve  is  left  behind,  one  may  antic-
pate  the  following  outcomes:  deaths  directly  related  to
he  procedure,  ≤  1%;  tamponade  requiring  a  thoracotomy,
 1%;  tamponade  requiring  subxyphoid  drainage,  1.5%;
evice  embolization,  1%;  intraprocedural  air  embolism,  ≤
%;  device  thrombosis  usually  occurring  within  weeks  after
evice  implantation,  4%,  causing  an  ischaemic  or  haemor-
hagic  CVA  in  <  1%.
cclusion of the LAA
ndications, non-indications and
ontraindications
ndications
he  results  of  the  PROTECT-AF  study  have  validated  the
oncept  of  percutaneous  occlusion  of  the  LAA  as  an  alterna-
ive  to  antivitamin  K  in  the  prevention  of  thromboembolisms
n  non-valvular  AF.  However,  the  level  of  proof  of  the  safety
nd  efﬁcacy  of  OACs  in  this  context  is  extremely  high,  sup-
orted  by  several  concordant  studies  in  several  thousands
f  patients.  The  power  of  these  studies  and  the  level
f  evidence  have  unquestionably  positioned  OACs  on  the
rontline  in  the  prevention  of  thromboembolic  events.  The
012  European  professional  practice  guidelines  regarding
he  management  of  AF  are  clear:  it  is  premature  to  offer  this
echnique  to  all  patients  who  are  at  high  risk  of  thrombotic
vents  and  candidates  for  OACs.  In  the  European  guidelines,
ercutaneous  occlusion  of  the  LAA  can  be  considered  for
atients  at  high  risk  of  thromboembolism,  in  whom  long-
erm  OACs  are  contraindicated  (class  IIb,  level  of  evidence
)  [21].
Gauging  the  absolute  or  relative  contraindications  to
ACs  may  be  challenging,  although  help  can  be  found
n  the  use  of  CHA2DS2-VASc  scores  to  estimate  throm-
oembolic  risk,  and  HAS-BLED  scores  to  estimate  the
aemorrhagic  risk  during  OAC  treatment  [21]. What  is
he  rationale  behind  these  contraindications?  How  should
 haemorrhage  developing  during  poorly  prescribed  OAC
reatment  or  of  potentially  curable  origin  be  considered?
ow  should  we  deal  with  a non-compliant  patient  or  a
atient  declining  long-term  OACs  for  questionable  reasons?
hese  contraindications  must,  therefore,  be  the  subject  of  a
ultidisciplinary  conversation,  in  which  experts  in  the  organ
t  the  origin  of  the  haemorrhagic  event  must  participate.
The  indication  for  the  occlusion  of  the  LAA  cited  in
he  European  guidelines  does  not  correspond  to  the  indica-
ion  applied  in  the  only  published  randomized  study  on  the
fﬁcacy  of  the  procedure,  although  it  is  clearly  the  main
ndication  in  clinical  practice.  In  the  European  ACP  registry,
early  80%  of  the  indications  were  related  to  a  high  haemo-
rhagic  risk,  9%  to  the  development  of  a haemorrhage  and
1%  to  the  development  of  a  CVA  during  OAC  treatment  [9].
While  the  choice  candidates  for  occlusion  of  the  LAA
re  patients  who  are  not  candidates  for  OACs,  prudence
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s  required  when  posing  the  indication  for  the  procedure
ecause,  in  this  often  frail  population:  the  risk  of  periproce-
ural  complications  is  high;  the  incidence  of  other  potential
auses  of  CVAs  is  high;  the  absence  of  OAC  treatment,  left
entricular  dysfunction  and  a  history  of  CVAs  are  associated
ith  a  high  prevalence  of  thrombi  outside  the  LAA  [2];  and
 formal  contraindication  to  OAC  raises  the  issue  of  what
ntithrombotic  strategy  must  be  adopted  after  occlusion  of
he  LAA.
In  some  cases,  several  questions  related  to  complicated
ndividual  circumstances  will  need  to  be  addressed.  The
ndications  will,  therefore,  be  based  on  multidisciplinary
valuations.  The  role  of  various  AF  therapies  will,  in  some
ases,  be  discussed  with  cardiologists  specialized  in  the
reatment  of  arrhythmias,  particularly  if  ablation  of  AF  is
ontemplated,  which  should  be  performed  before  occlusion
f  the  LAA.
Occlusion  of  the  LAA  has  been  considered  for  patients
ho  have  had  a  CVA  despite  optimal  OAC  treatment.  While
his  indication  seems  reasonable,  the  level  of  evidence  in  its
avour  remains  weak,  and  other  treatment  options  must  be
onsidered,  such  as  a  different  antithrombotic  or  its  combi-
ation  with  an  antiplatelet  agent.  Other  putative  sources  of
VAs  will  need  to  be  excluded  and  the  indication  validated
y  targeted  studies.
on-indications
n  view  of  the  strong  evidence  of  safety  and  efﬁcacy  of  OACs,
eluctance  of  the  patient  to  be  anticoagulated  does  not  rep-
esent  a  valid  indication  for  occlusion  of  the  LAA.  Neither  are
F  developing  in  recipients  of  valvular  prostheses  or  patients
resenting  with  rheumatic  mitral  valve  disease,  given  the
igh  risk  of  thrombi  elsewhere  in  the  atrium.
ontraindications
he  presence  of  a  thrombus  in  the  LAA  or  the  left  atrial
avity  is  a  temporary  contraindication  for  implantation  of
n  occlusion  system.  In  special  cases,  this  contraindica-
ion  might  be  waived  after  discussion  among  experts.  Rare
natomical  variants  of  the  LAA  preclude  the  implantation  of
ny  device  currently  available.
reprocedural evaluation
ultidisciplinary conﬁrmation of the
ndication
he  indication  for  the  implantation  of  a  LAA  occlusion
ystem  must  be  based  upon  consensus  of  experts  in  multi-
le  disciplines,  including  an  interventional  cardiologist  or
rrhythmia  specialist  with  personal  experience  with  the
rocedure,  a  non-interventional  cardiologist  specialized  in
chocardiography  and  in  this  technique,  a  specialist  in  the
rgan  responsible  for  the  contraindication  to  OAC  and,  if
ppropriate,  a  geriatrician.  The  various  AF  treatments  and,
n  particular,  the  possible  use  of  ablation  must  be  discussed
ith  an  arrhythmia  specialist.  The  patient  must  be  informed
f  the  various  treatment  options  and  respective  risks,  includ-
ng  that  of  general  anaesthesia,  which  must  be  gauged
uring  a  dedicated  consultation.
i
i
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In  the  context  of  high  haemorrhagic  risk  from  OACs,  the
ndication  for  occlusion  of  the  LAA  is  often  posed  by  practi-
ioners  faced  with  a  major  haemorrhagic  event  and  high  risk
f  recurrence,  which  might  involve  all  systems  (e.g.  cen-
ral  nervous,  musculoskeletal,  digestive,  urogenital,  etc.).
ne  must  determine  whether  an  underlying  curable  cause
f  haemorrhagic  event  is  present  and  is  being  treated.
eri- and post-procedural antithrombotic
trategy
on-cardiologists  specialized  in  the  organ  that  has  bled
ust  be  asked  about  the  antithrombotic  coverage  that
an  be  prescribed  with  an  acceptable  risk  of  bleeding
uring  and  after  the  procedure,  in  view  of  the  risk  of
hrombus  formation  on  the  surface  of  the  device.  Antico-
gulation,  using  unfractionated  heparin,  is  recommended
uring  the  implantation  procedure,  aiming  for  an  activated
lotting  time  of  >  250  seconds.  Antithrombotic  prevention
s  recommended  after  implantation,  while  endothelializa-
ion  of  the  device  is  taking  place.  In  PROTECT-AF,  warfarin
as  administered  for  6  weeks,  followed  by  an  antiplatelet
egimen  for  ≥  6  months,  in  the  protocol  described  ear-
ier.  That  antithrombotic  protocol,  however,  was  reserved
or  antivitamin  K  candidates.  Even  when  administered
rieﬂy,  an  anticoagulant  may  be  risky  and  contraindicated  in
atients  with  histories  of  cerebral  haemorrhage.  The  opti-
al  antithrombotic  strategy  for  candidates  for  percutaneous
cclusion  of  the  LAA  is  chosen  by  the  ‘‘Heart-Team’’  and
he  specialist  who  determined  that  OAC  was  contraindi-
ated,  depending  on  the  patient’s  haemorrhagic  risk.  Dual
ntiplatelet  therapy  was  studied  for  6  months  in  the  ASAP
egistry,  with  noteworthy  results  [5].  Other  options  that
an  be  considered  on  a  case-by-case  basis  include  single
ntiplatelet  therapy  or  no  antithrombotic  treatment,  as
ong  as  approved  by  consensus,  as  mentioned  earlier.  No
ata  are  available  on  the  use  of  direct  OACs  in  this  con-
ext,  although  this  new  pharmaceutical  class  needs  to  be
tudied.
maging of the LAA
etailed  imaging  of  the  LAA,  including,  at  a  minimum,  TOE,
ust  be  performed  before  the  procedure  to  conﬁrm  its
easibility  and  exclude  possible  contraindications.  A  scan
nabling  tridimensional  reconstruction  of  the  appendage  is
ecommended.  These  different  imaging  techniques  reveal
he  shape,  depth  and  dimensions  of  the  LAA  and  its  ostium,
nd  the  number  of  its  lobes,  and  allow  conﬁrmation  of  the
bsence  of  thrombus  and  selection  of  the  type  and  size  of
evice.
rocedural environment
he  procedure  must  be  performed  under  general  anaesthe-
ia  in  order  to  guide  it  by  mandatory  TOE.  The  activated
lotting  time  needs  to  be  measured  regularly  throughout  the
rocedure  to  verify  the  proper  anticoagulation  level.The  X-ray  equipment  must  possess  a  number  of  character-
stics.  The  C  arm  must  enable  all  ﬂuoroscopic  projections,
ncluding  extremes.  The  use  of  a  mobile  C  arm  of  the  kind
sed  in  operating  rooms  is  discouraged  because  of  the  low
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hPercutaneous  occlusion  of  the  left  atrial  appendage:  An  exp
quality  of  the  image,  which  does  not  allow  visualization  of
poorly  radio-opaque  devices.
The  X-ray  tube  and  image  intensiﬁer  or  ﬂat  plate  must
be  of  high  quality  and  regularly  maintained.
The  imaging  chain  must  be  digital  (real-time  digital
scope  and  graphics),  enabling  the  immediate  review  of
all  sequences.  A  quantiﬁcation  system  with  or  without
automatic  calibration  must  be  available  to  carry  out  the
angiographic  measurements  of  the  LAA  and  compare  them
with  the  echocardiographic  measurements.
The  procedural  space  must  be  equipped  with  the
instrumentation  needed  to  monitor  various  signals  during
the  procedure,  including  continuous,  two-channel  elec-
trocardiography,  non-invasive  blood  pressure  and  oxygen
saturation,  and  intracardiac  pressures.  In  accordance  with
current  regulation,  the  reanimation  equipment  (which  must
be  regularly  checked)  must  be  present  in  the  room,  includ-
ing:  pharmaceutical  solutions;  a  deﬁbrillator  and  external
cardiac  pacing  system;  pericardiocentesis;  instruments  for
extraction  and  retrieval  of  intracardiac  devices;  oxygen-
ation,  intubation  and  ventilation  equipment;  perfusion  kits;
electric  syringes;  pharmaceutical  carts;  and  a  cell  saver-
type  system  of  blood  salvage.  The  staff  must  be  trained  to
use  this  equipment  in  an  emergency,  to  handle  complications
or  prepare  the  transfer  of  an  unstable  patient  to  a  rean-
imation  unit  or  operating  room.  The  device  implantation
room  must  fulﬁl  the  norms  of  an  interventional  cardiology
or  cardiac  arrhythmia  treatment  room,  or  of  a  so-called
hybrid  suite.  It  must,  in  particular,  be  spacious  enough  to
allow  rapid  mobilization  of  the  staff  around  the  patient
to  proceed  with  reanimation  or  emergency  surgery,  if
necessary.
A  post-procedural  recovery  room  must  be  near  the
interventional  procedure  suite  to  receive  and  watch  the
patients  after  the  procedure,  and  must  be  equipped  with  all
the  previously  described  reanimation  essentials,  including
electrocardiographic,  blood  pressure  and  oximeter  oscillo-
scopes.  The  recording  of  a  complete  electrocardiogram  must
be  possible,  if  needed.
This  technique  is  associated  with  a  periprocedural  risk
that  is  accentuated  by  the  old  age  and  frailty  of  the  popu-
lation,  often  presenting  with  major  concomitant  disorders.
The  main  risk  is  tamponade  due  to  injury  to  the  LAA,  caused
by  the  device,  a  guide  or  a  catheter,  or  by  a  traumatic
transseptal  puncture.  This  complication  must  be  directly
manageable  on  site  by  percutaneous  drainage  by  the  oper-
ator,  using  special  instrumentation.  The  precise  cause  of
bleeding  must  be  rapidly  identiﬁed,  which  might  require  a
surgical  subxyphoid  puncture  or,  less  often,  a  sternotomy.
Device  migration  is  another  major,  although  more  rare,
complication;  its  percutaneous  retrieval  is  often  highly  chal-
lenging  when  the  device  has  migrated  in  the  abdominal
aorta.  Because  of  their  size,  most  devices  remain  in  the
left  cardiac  chambers,  exposing  the  valves  to  traumas  or
dysfunction  and  mandating  surgical  intervention.
In  recent  years,  the  LAA  has  been  occluded  by  experi-
enced  operators  in  high-volume  medical  centres  equipped
with  a  cardiac  surgery  or  cardiothoracic  surgery  service
staffed  with  operators  capable  of  performing  a  sternotomy
(or  any  other  cardiothoracic  approach,  if  necessary)  and
repairing  a  cardiac  tear.  These  recommendations  were  for-
mulated  by  the  device  manufacturers,  based  on  publications
i
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nd  on  their  experience  in  the  marketing  of  these  prod-
cts.  Since  2013,  all  procedures  carried  out  in  France  have
een  entered  in  the  French  Left  Atrial  Appendage  Closure
FLAAC)  registry.  As  in  several  other  European  countries,  the
rench  High  Authority  for  Health  has  issued  support  for  the
reation  of  a  document  stipulating  the  performance  of  this
rocedure,  underscoring  the  need  for  an  environment  offer-
ng  back-up  cardiac  surgery.  This  provisional  document  will
elp  to  determine  the  reimbursement  by  insurance  compa-
ies,  which,  for  the  time  being,  are  considering  coverage  for
he  Watchman  system  and,  recently,  the  ACP  system.  These
ecommendations  will  need  to  be  re-evaluated  on  the  basis
f  results,  complications,  the  use  of  back-up  surgery  and
he  conditions  prompting  the  use  of  surgery.  For  example,
sing  the  FLAAC  registry,  the  rate  of  complications  requiring
mergency  cardiac  surgery  will  need  to  be  examined  after
 or  2  years  of  activity.  Participation  in  this  registry  must
e  compulsory  and  the  data  collection  comprehensive,  to
valuate  French  medical  practice  in  detail.  Until  then,  it
s  imperative  that  operators  barred  from  performing  this
rocedure  despite  their  qualiﬁcation  can  obtain  authoriza-
ion  from  cardiothoracic  centres  to  implant  LAA  occluding
evices  by  contractual  agreement.
Occlusion  of  the  LAA  is  a  preventive,  non-
harmacological  treatment,  which,  except  for  its
omplications,  is  elective.  No  intent  to  proceed  with
he  device  implantation  within  the  shortest  delay  can
ustify  its  performance  in  an  environment  that  does  not
ulﬁl  the  safety  criteria  described  earlier.
reatment centre activity and operator
xperience
he  beneﬁt  expected  from  this  preventive  treatment  hinges
irectly  on  the  risk  associated  with  the  procedure.  The
ata  available  have  been  gathered  from  medical  centres
nd  for  operators  whose  procedural  activity  is  variable.  The
ost-hoc  analysis  of  PROTECT-AF  revealed  that  ‘‘the  oper-
tor’s  experience  is  an  important  factor  when  evaluating
he  efﬁcacy  and  safety  of  the  procedure’’  [22].  Overall,  the
tudies  have  shown  a  decrease  in  the  incidence  of  proce-
ural  complications  with  an  increase  in  the  experience  of  the
edical  centre  and  an  inescapable  learning  curve.  In  order
o  limit  the  worst  consequences,  the  LAA  occlusion  system
ust  be  implanted  by  a  general  interventional  cardiolo-
ist  or  cardiac  arrhythmia  specialist  experienced  in  cardiac
atheterization  and  the  management  of  its  complications.
he  LAA  is  anatomically  widely  variable  in  its  location,  size
nd  shape,  mandating  a sufﬁcient  number  of  procedures
o  acquire  the  necessary  proﬁciency.  Transseptal  puncture,
 major  procedural  step  with  known  risks,  must  be  mas-
ered  by  the  operating  team,  while  the  medical  centre  must
e  in  possession  of  a ‘‘level  3’’  authorization  to  perform
ighly  complex  interventions,  deﬁned  by  the  regional  health
gencies  (ARS)  in  the  master  plans  for  the  organization  of
ealthcare  (SROS).
Because  the  technique  is  new  and  often  used  spar-
ngly,  especially  in  France,  no  study  has  clearly  identiﬁed
 threshold  number  of  procedures  beyond  which  the  risk
f  complications  diminishes.  Whatever  the  interventional
rocedure  performed  in  cardiology,  low-volume  centres
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O66  
re  notoriously  observing  a  higher  risk  of  complications.
n  the  case  of  AF  ablation,  a  North  American  registry  of
3,801  procedures  found  that  fewer  than  25  procedures
er  operator  and  50  procedures  per  centre  predict  poor
esults  [23].
TOE  guidance  is  key  to  the  success  of  the  procedure,
aking  it  possible  to:  take  the  measurements  needed  for
election  of  device  and  site  of  implantation;  conﬁrm  the
ccurate  and  effective  placement  of  the  device  before  its
elease;  and  detect  possible  complications,  particularly  the
evelopment  of  a  pericardial  effusion  or  dislodgement  of
he  device.  Thus,  the  interventional  team  must  include
n  expert  echocardiographer  trained  in  transoesophageal
rocedures  and  in  the  handling  of  the  various  implantable
evices.
Implantation  of  the  available  devices  requires  speciﬁc
raining.  Under  current  circumstances,  the  interventional
eam,  which  includes  the  cardiologist  or  the  interventional
rrhythmia  expert  and  the  cardiologist  echocardiographer
nvolved  in  the  procedure,  must  have  completed  the  train-
ng  offered  and  be  certiﬁed  by  the  device  manufacturers.
he  initial  procedures  carried  out  in  a  centre  that  fulﬁls  all
he  conditions  mentioned  earlier,  by  operators  whose  train-
ng  has  been  certiﬁed  by  the  device  manufacturers,  must  be
acked  by  a  physician-trainer  accredited  by  each  manufac-
urer,  until  the  operator  is  fully  autonomous.  Consequently,
ased  on  current  information,  it  seems  legitimate  to  request
rom  the  centres  that  implant  or  wish  to  implant  LAA  occlud-
rs,  that  they:  are  able  to  gather  a  multidisciplinary  team
o  pose  the  indication;  reach,  within  3  years,  a  minimum
f  25  procedures  per  year,  to  acquire  the  highest  techni-
al  proﬁciency  and  a  risk  of  complications  consistent  with
he  most  recent  published  data  [21,23];  train  all  members
f  the  interventional  team  in  the  use  of  the  implanted  sys-
em;  attain  proﬁciency  of  the  interventional  team  in  the
erformance  of  ≥  30  transseptal  catheterization  per  year;
nclude  a  reanimation  service,  a  cardiac  intensive  care  unit,
 cardiothoracic  service  and  an  expeditious  procedure  for
he  management  of  embolic  complications.
ost-implantation follow-up
n  LAA  occlusion  device  must  be  followed  after  its  implanta-
ion.  A  thrombus  on  the  surface  of  the  device,  a  pericardial
ffusion  with  or  without  tamponade,  and  dislodgement
f  the  device  with  or  without  embolization,  are  among
he  reported  complications  occurring  in  the  weeks  after
mplantation.  In  the  PROTECT-AF  trial  and  the  CAP  registry,
ollow-up  was  based  on  a  clinical  and  TOE  evaluation  at  45
ays  and  at  6  months  and  12  months  to  verify,  in  particu-
ar,  the  absence  of  residual  periprosthetic  leak.  A  follow-up
rogramme  with  a  ﬁrst  TOE  before  discontinuation  of  anti-
oagulation  or  bi-antithrombotic  therapy  and  a  second  one
etween  4  and  6  months  later  to  verify  the  absence  of
hrombus  and  residual  periprosthetic  leak  seems  sufﬁcient
o  detect  and  treat  the  possible  complications  attributable
o  the  device  and  allows  an  individual  adaptation  of  the
ntithrombotic  treatment.  As  the  repetitive  performance
f  TOE  might  be  risky  in  an  elderly  population,  cardiac
canning  may  be  an  acceptable  alternative.  The  tolerance
f,  and  compliance  with,  the  temporary  antithrombotic
p
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egimen  evaluated  before  the  procedure  should  be  re-
valuated  and  reconsidered  during  follow-up,  if  necessary.
onclusions
he  beneﬁt  of  percutaneous  occlusion  of  the  LAA  in
aroxysmal,  persistent  or  permanent  AF  has  been  demon-
trated  in  a  randomized  controlled  trial  in  patients  at
isk  of  thromboembolism  with  an  indication  for  OACs  and
ithout  contraindication  to  OACs.  Nowadays,  this  non-
harmacological  treatment  is  an  option  recommended  for
atients  in  AF  and  in  whom  long-term  OAC  treatment  is
ndicated  but  contraindicated,  based  on  data  acquired  by
egistries  and  preliminary  studies.
The  Rhythm  and  Cardiac  Pacing  and  the  Atheroma  and
nterventional  Cardiology  Groups  of  the  French  Society  of
ardiology  believe,  from  both  the  literature  and  the  actual
herapeutic  needs  of  a  selected  population,  that  percuta-
eous  occlusion  of  the  LAA  may  play  a  key  role  in  preventing
hromboembolisms  in  non-valvular  AF.
The  challenging  indication  must  emanate  from  a  mul-
idisciplinary  consensus  after  a  case-by-case  estimation  of
he  risk—beneﬁt  ratio.  This  preventive  therapy  is  associ-
ted  with  major  complications,  which  can  limit  its  beneﬁt.
owever,  a  clear  decrease  in  the  incidence  of  these
omplications  has  been  documented  as  experience  is  gained
n  the  performance  of  the  procedure.  The  rate  of  major
omplications  in  the  hands  of  an  experienced  team  is
urrently  estimated  at  <  3%,  in  contrast  to  the  >  8%  per
ear  risk  of  CVAs  in  patients  presenting  with  a  CHA2DS2-
ASc  score  ≥  2 in  the  absence  of  OAC  treatment  [24].
n  the  current  state  of  knowledge  and  in  accordance
ith  the  European  consensus  published  at  the  time  this
tatement  was  written  [25], this  procedure  must  be  per-
ormed  by  trained  cardiologists,  whose  activity  is  sufﬁcient
o  justify  its  performance  and  who  practice  under  the
afest  possible  conditions.  As  the  expertise  of  the  medi-
al  centres  increases,  the  risk—beneﬁt  ratio  decreases.
ome  potentially  serious  complications  might  require  urgent
anagement  by  the  interventional  or  surgical  team,  or  by
oth.
In  this  context,  the  FLAAC  registry  has  been  initiated  by
he  French  Society  of  Cardiology,  with  a  view  to  including  all
atients  who  undergo  this  procedure.  Inclusion  in  this  reg-
stry  should  be  mandatory  and  comprehensive,  in  order  to
valuate  reliably  the  long-term  results  and  complications  of
his  technique,  as  well  as  the  appropriateness  of  the  regu-
atory  constraints  imposed  on  its  performance.
Finally,  the  implantation  of  LAA  occlusion  devices  for
ndications  other  than  those  discussed  in  this  consensus
tatement  should  take  place  within  carefully  planned  clini-
al  research  protocols.
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